Literature DB >> 2478218

Identification of and partial characterization of platelet vitronectin: evidence for complex formation with platelet-derived plasminogen activator inhibitor-1.

K T Preissner1, S Holzhüter, C Justus, G Müller-Berghaus.   

Abstract

Vitronectin (VN; = complement S-protein), a plasma glycoprotein that is also associated with extracellular sites, was identified in washed human platelets contaminated with less than 0.05% of plasma VN. A specific enzyme-linked immunosorbent assay (ELISA) for VN has been developed and was used to detect and to quantitate VN in detergent extracts of washed platelets with 8.1 +/- 4.6 micrograms/10(9) platelets (n = 10), representing about 0.8% of the plasma VN pool. Platelet and plasma VN were similar by immunochemical criteria using Western-blot analysis, although platelet VN was mainly found as partially proteolyzed polypeptide. Total release of platelet VN occurred at optimal doses of Ca-ionophore 23187 or thrombin, whereas no VN was released by platelet treatment with digitonin or Staphylococcus alpha-toxin. During stimulation of washed platelets with various concentrations of thrombin, the nearly concomitant release of VN and plasminogen activator inhibitor-1 (PAI-1) together with platelet factor 4 indicated the association of VN with inner-platelet storage granules. Furthermore, platelet VN and PAI-1 in Ca-ionophore releasates comigrated during ultracentrifugation in high mol wt fractions of sucrose density gradients, indicating a possible association of both components. Complex formation of platelet VN and PAI-1 was verified by a sensitive enzyme-linked immunosorbent assay (ELISA) and accounts at least in part for a high molecular form of platelet VN. The identification of platelet VN and its binding to platelet PAI-1 raises the possibility that VN, in contrast to other adhesive proteins, may participate in localized regulatory functions of blood coagulation and fibrinolysis in platelet-matrix interactions and the protection of the matrix against proteolysis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2478218

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Plasminogen in proliferative vitreoretinal disorders.

Authors:  P Esser; K Heimann; K U Bartz-Schmidt; P Walter; R Krott; M Weller
Journal:  Br J Ophthalmol       Date:  1997-07       Impact factor: 4.638

2.  The cluster of basic amino acids in vitronectin contributes to its binding of plasminogen activator inhibitor-1: evidence from thrombin-, elastase- and plasmin-cleaved vitronectins and anti-peptide antibodies.

Authors:  Z Gechtman; A Belleli; S Lechpammer; S Shaltiel
Journal:  Biochem J       Date:  1997-07-15       Impact factor: 3.857

Review 3.  The role of vitronectin as multifunctional regulator in the hemostatic and immune systems.

Authors:  K T Preissner
Journal:  Blut       Date:  1989-11

4.  Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: characterization of the binding of vitronectin to osteonectin (BM40, SPARC).

Authors:  S Rosenblatt; J A Bassuk; C E Alpers; E H Sage; R Timpl; K T Preissner
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

5.  Plasminogen activator inhibitor-1 removal using dextran sulphate columns. Evidence of PAI-1 homeostasis.

Authors:  Vincent M G Maher; Yuri Kitano; Clare Neuwirth; Graham J Davies; Attilio Maseri; Gilbert R Thompson; Felicita Andreotti
Journal:  J Thromb Thrombolysis       Date:  2008-07-30       Impact factor: 2.300

6.  Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro.

Authors:  D T Eitzman; W P Fay; D A Lawrence; A M Francis-Chmura; J D Shore; S T Olson; D Ginsburg
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

7.  The significance of vitronectin in proliferative diabetic retinopathy.

Authors:  P Esser; M Bresgen; M Weller; K Heimann; P Wiedemann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-08       Impact factor: 3.117

8.  Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.

Authors:  H J Ehrlich; R K Gebbink; K T Preissner; J Keijer; N L Esmon; K Mertens; H Pannekoek
Journal:  J Cell Biol       Date:  1991-12       Impact factor: 10.539

9.  Proteomic analysis of human plasma in chronic rheumatic mitral stenosis reveals proteins involved in the complement and coagulation cascade.

Authors:  Somaditya Mukherjee; Mashanipalya G Jagadeeshaprasad; Tanima Banerjee; Sudip K Ghosh; Monodeep Biswas; Santanu Dutta; Mahesh J Kulkarni; Sanjib Pattari; Arun Bandyopadhyay
Journal:  Clin Proteomics       Date:  2014-09-24       Impact factor: 3.988

10.  Fluid Shear Stress and Fibroblast Growth Factor-2 Increase Endothelial Cell-Associated Vitronectin.

Authors:  Justin G Mathew; Sarah Basehore; Alisa Morss Clyne
Journal:  Appl Bionics Biomech       Date:  2017-06-01       Impact factor: 1.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.